These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 18207397)
1. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647 [TBL] [Abstract][Full Text] [Related]
3. Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. Lacombe P; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Gallant M; Girard Y; Huang Z; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini JA; Masson P; Nicholson DW; Nicoll-Griffith DA; Salem M; Styhler A; Young RN Bioorg Med Chem Lett; 2009 Sep; 19(17):5266-9. PubMed ID: 19640717 [TBL] [Abstract][Full Text] [Related]
4. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678 [TBL] [Abstract][Full Text] [Related]
5. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors. He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096 [TBL] [Abstract][Full Text] [Related]
6. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors. Kagayama K; Morimoto T; Nagata S; Katoh F; Zhang X; Inoue N; Hashino A; Kageyama K; Shikaura J; Niwa T Bioorg Med Chem; 2009 Oct; 17(19):6959-70. PubMed ID: 19744860 [TBL] [Abstract][Full Text] [Related]
8. Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors. Lacombe P; Deschênes D; Dubé D; Dubé L; Gallant M; Macdonald D; Mastracchio A; Perrier H; Charleson S; Huang Z; Laliberté F; Liu S; Mancini JA; Masson P; Salem M; Styhler A; Girard Y Bioorg Med Chem Lett; 2006 May; 16(10):2608-12. PubMed ID: 16516471 [TBL] [Abstract][Full Text] [Related]
9. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors. Kim I; Song JH; Park CM; Jeong JW; Kim HR; Ha JR; No Z; Hyun YL; Cho YS; Sook Kang N; Jeon DJ Bioorg Med Chem Lett; 2010 Feb; 20(3):922-6. PubMed ID: 20053559 [TBL] [Abstract][Full Text] [Related]
11. Pharmacology of a novel, orally active PDE4 inhibitor. Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962 [TBL] [Abstract][Full Text] [Related]
12. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895 [TBL] [Abstract][Full Text] [Related]
13. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045 [TBL] [Abstract][Full Text] [Related]
14. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity. Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103 [TBL] [Abstract][Full Text] [Related]
15. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447 [TBL] [Abstract][Full Text] [Related]
16. Rhodanine derivatives as novel inhibitors of PDE4. Irvine MW; Patrick GL; Kewney J; Hastings SF; MacKenzie SJ Bioorg Med Chem Lett; 2008 Mar; 18(6):2032-7. PubMed ID: 18304812 [TBL] [Abstract][Full Text] [Related]
17. New orally active PDE4 inhibitors with therapeutic potential. Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087 [TBL] [Abstract][Full Text] [Related]
18. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874 [TBL] [Abstract][Full Text] [Related]
19. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR. Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Nikpour M; Sadeghian H; Saberi MR; Nick RS; Seyedi SM; Hosseini A; Parsaee H; Bozorg AT Bioorg Med Chem; 2010 Jan; 18(2):855-62. PubMed ID: 20005117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]